Fluorescence in situ hybridization (FISH): An increasingly demanded tool for biomarker research and personalized medicine

被引：59

作者：

Hu L. ^{[1
,6
]}

Ru K. ^{[1
,2
]}

Zhang L. ^{[1
,3
]}

Huang Y. ^{[4
]}

Zhu X. ^{[1
,3
,6
]}

Liu H. ^{[1
,6
]}

Zetterberg A. ^{[5
]}

Cheng T. ^{[1
,6
]}

Miao W. ^{[1
,6
]}

机构：

[1] State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

[2] Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

[3] Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

[4] Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin

[5] Department of Oncology-Pathology and Karolinska Cancer Center, Karolinska Institute, Stockholm

[6] Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing Road 288, Tianjin

来源：

Biomarker Research | / 2卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Biomarkers; Fluorescence in situ hybridization (FISH); Genetic aberrations; Hematopoietic malignancies; Personalized medicine; Solid tumors;

D O I：

10.1186/2050-7771-2-3

中图分类号：

学科分类号：

摘要：

Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well. © 2014 Hu et al.; licensee BioMed Central Ltd.

引用

共 102 条

[91]

Schramm M., Wrobel C., Born I., Kazimirek M., Pomjanski N., William M., Kappes R., Gerharz C.D., Biesterfeld S., Bocking A., Equivocal cytology in lung cancer diagnosis: improvement of diagnostic accuracy using adjuvant multicolor FISH, DNA-image cytometry, and quantitative promoter hypermethylation analysis, Cancer Cytopathol, 119, 3, pp. 177-192, (2011)

[92]

Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., Kempski H., Moorman A.V., Titley I., Swansbury J., Et al., Genetic variegation of clonal architecture and propagating cells in leukaemia, Nature, 469, 7330, pp. 356-361, (2011)

[93]

Janssens A., Van Roy N., Poppe B., Noens L., Philippe J., Speleman F., Offner F., High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature, Eur J Haematol, 89, 1, pp. 72-80, (2012)

[94]

Wawrzyniak E., Kotkowska A., Blonski J.Z., Siemieniuk-Rys M., Ziolkowska E., Giannopoulos K., Robak T., Korycka-Wolowiec A., Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance, Eur J Haematol, 92, 2, pp. 91-101, (2013)

[95]

Wang Y.C., Hu L.P., Lin D., Li C.W., Yuan T., Jia Y.J., Tian Z., Tang K.J., Wang M., Wang J.X., Detection of heterogeneity and evolution of subclones in t(8

[96]

21) AML by QM-FISH, Zhonghua Xue Ye Xue Za Zhi, 34, 10, pp. 844-850, (2013)

[97]

Vital A.L., Tabernero M.D., Crespo I., Rebelo O., Tao H., Gomes F., Lopes M.C., Orfao A., Intratumoral patterns of clonal evolution in gliomas, Neurogenetics, 11, 2, pp. 227-239, (2010)

[98]

Zhang S., Shao Y., Hou G., Bai J., Yuan W., Hu L., Cheng T., Zetterberg A., Zhang J., QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer, Tumour Biol, (2013)

[99]

Tomao F., Papa A., Rossi L., Strudel M., Vici P., Lo Russo G., Tomao S., Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach, J Exp Clin Cancer Res, 32, (2013)

[100]

Li Z., CD133: a stem cell biomarker and beyond, Exp Hematol Oncol, 2, 1, (2013)

← 2 3 4 5 6 7 8 9 10 11 →